Allergan's Sensar Intraocular Lens Receives U.S. Marketing Approval.

Business Editors and Health/Medical Writers

IRVINE, Calif.--(BW HealthWire)--Feb. 3, 2000

Allergan, Inc. (NYSE: AGN) today announced it has received approval from the United States Food and Drug Administration (FDA) to market the Sensar(TM) Foldable Acrylic Posterior Chamber Intraocular Lens (IOL) in the United States.

The Sensar(TM) IOL is a next generation acrylic IOL. The Sensar(TM) IOL's material and design were developed to minimize some of the unwanted side effects of some currently available acrylic lenses marketed in the U.S. The Sensar(TM) IOL is delivered into the eye through a patented device, The Unfolder(TM) Sapphire Series Implantation System manufactured by Allergan. This system provides ophthalmic surgeons with unparalleled control, small incision capability, and a sterile delivery technology.

&uot;The approval of the Sensar(TM) IOL provides Allergan with an advanced technology product that will enable the Company to aggressively pursue a sizeable segment of the ophthalmic surgical foldable IOL market,&uot; said David E. I. Pyott, Allergan's President and Chief Executive Officer. &uot;We are particularly pleased with this FDA approval, as the Sensar(TM) IOL will complement Allergan's existing portfolio of leading products for small-incision cataract surgery, such as the Array(R) Multifocal IOL, the Sovereign(TM) phacoemulsification system, and the market leading PhacoFlex II(R) foldable silicone IOLs.&uot;

A cataract is the condition in which the natural refractive lens in the eye becomes progressively cloudy. Usually age-related, this clouding obstructs the passage of light and can lead to functional blindness. Cataracts are generally treated by surgically removing the natural clouded lens and replacing it with an artificial lens, an IOL. An estimated 6 million IOLs were implanted worldwide in 1999.

Any of the above statements that refer to the company's estimated or anticipated future results are forward-looking and reflect the company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses, including competitive conditions and changing market conditions, and product performance, including patients, physicians and managed care organization's acceptance of the Sensar(TM) IOL. These forward-looking statements represent the company's judgment only as of the date of this press release. Actual results could differ materially from those described in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Additional information concerning these factors can be found in press releases as well as in the company's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading &uot;Certain Factors and Trends Affecting Business&uot; in the company's 1998 Form 10-K. Copies of company press releases and additional information about Allergan are available on our Web Site at www.allergan.com, or you can contact our Investor Relations Department by calling 714-246-4636.

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.